Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Ritchie

Showing results (81-90 of 123) with videos related to

Pageof 13
Sort By:
The Lancet. Psychiatry|June 9, 2018
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trialRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Neuroepidemiology|February 5, 2020
Dementia Research Fit for the Planet: Reflections on Population Studies of Dementia for Researchers and Policy Makers AlikeCarol E Brayne, Linda E Barnes, Monique M B Breteler, et al.
Neurology|June 11, 2024
Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease HeterogeneitySophie E Mastenbroek, Arianna Sala, David Vállez García, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthAudrey Low, Georgios Ntailianis, Kamen A Tsvetanov, et al.
Health Technology Assessment (Winchester, England)|December 4, 2018
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCTRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 19, 2020
The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countriesMark A Dubbelman, Merike Verrijp, David Facal, et al.
Alzheimer'S Research & Therapy|November 1, 2018
Secondary prevention of Alzheimer's dementia: neuroimaging contributionsMara Ten Kate, Silvia Ingala, Adam J Schwarz, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Brain : a Journal of Neurology|August 16, 2021
Reply: Functional cognitive disorder: dementia's blind spotHarriet A Ball, Laura McWhirter, Clive Ballard, et al.
The Lancet. Neurology|October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesRobert Howard, Rupert McShane, James Lindesay, et al.
Pageof 13

Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
The Lancet. Psychiatry|June 9, 2018
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trialRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Neuroepidemiology|February 5, 2020
Dementia Research Fit for the Planet: Reflections on Population Studies of Dementia for Researchers and Policy Makers AlikeCarol E Brayne, Linda E Barnes, Monique M B Breteler, et al.
Neurology|June 11, 2024
Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease HeterogeneitySophie E Mastenbroek, Arianna Sala, David Vállez García, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthAudrey Low, Georgios Ntailianis, Kamen A Tsvetanov, et al.
Health Technology Assessment (Winchester, England)|December 4, 2018
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCTRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 19, 2020
The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countriesMark A Dubbelman, Merike Verrijp, David Facal, et al.
Alzheimer'S Research & Therapy|November 1, 2018
Secondary prevention of Alzheimer's dementia: neuroimaging contributionsMara Ten Kate, Silvia Ingala, Adam J Schwarz, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Brain : a Journal of Neurology|August 16, 2021
Reply: Functional cognitive disorder: dementia's blind spotHarriet A Ball, Laura McWhirter, Clive Ballard, et al.
The Lancet. Neurology|October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesRobert Howard, Rupert McShane, James Lindesay, et al.
Pageof 13